- Screener
- Securities US
- Merck & Co Inc
Merck & Co Inc
$77.82
-$0.11
-0.14%
21 Apr 20:00
$75.93
$134.63
52 weeks low/high
Market sentiment
Section about market participants' moods: bulls holding long positions (“longs”) and bears holding short positions (“shorts”).
Overall assessment
bearish sentiment is waning
9day with a yield of-3.92%
Long
100.00%Short
0.00%| Index | Bulls | Bears |
|---|---|---|
Confidence | — | |
Support | — | |
Cash flows | — |
Momentum
Indicators for analyzing trends in the instrument. Based on them you can choose the optimal moment to open or close a position.
Return/MDD
-0.84Sentiment
BearishStart Date
03.25.2025Duration
23Yield
-11.22%Avg.Yield
-8.02%
Volatility
1.92%Max MDD
-13.39%Avg. MDD
-13.01%Min Price
RUB 76.46Max Price
RUB 89.71
Protective stop levels
S/L 5%RUB 80.28 | S/L 10%RUB 84.11 | S/L 15%RUB 87.93 | |
|---|---|---|---|
Day | 13.21% | 0.01% | 0.00% |
Week | 50.07% | 7.85% | 0.52% |
Month | 74.25% | 39.06% | 17.23% |
Technical analysis
- Trend ClassLinear Down
- Trend PowerStrong trend
- PatternChannel
- EMA-20Bearish reversal2025-03-21 the price crossed down the moving average line and demonstrates a downside trend.
- EMA-50Bearish reversal2025-03-21 the price crossed down the moving average line and demonstrates a strong downside trend.
- EMA-1002024-07-30 the price crossed down the moving average line and demonstrates a strong downside trend.
- StochasticBearish recoveryThe stochastic indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: main and signal line crossing.
- RSIBullish reversalRSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.
- MACDBearish WeakeningOscillator MACD is in the negative territory it's lower than the signal line and grows. These factors mean that the falling trend persists, but the growth rate is declining. Last signal: entry into the oversold zone.
- Candle pattern typeDark Clouds CoverIs a candlestick pattern whereby a black candlestick opens above a white candlestick's close and below its midpoint.Considered to be a bearish reversal pattern.Date of signal:
Prices and risks
Price
| Change | Change by industry | Min. | Max. | Volume | |
|---|---|---|---|---|---|
| Yesterday | 0.84% | 4.11% | $77.30 | $78.19 | 14.91M |
| Week | -1.39% | 1.96% | $75.93 | $80.02 | 3.02B |
| Month | -16.17% | 0.15% | $75.93 | $94.68 | 15.91B |
| 3 Months | -18.90% | 5.36% | $75.93 | $100.15 | 51.73B |
| 6 Months | -26.61% | 19.73% | $75.93 | $109.17 | 85.63B |
| Year | -37.96% | 0.64% | $75.93 | $134.63 | 154.14B |
| 3 years | -9.49% | 56.01% | $75.93 | $134.63 | 397.45B |
| 5 years | 4.04% | 76.51% | $68.49 | $134.63 | 698.47B |
| All time | 103.64% | 54.85% | $19.15 | $134.63 | 670.15B |
Volatility
| MRK | By industry | |
|---|---|---|
| Yesterday | 23.87% | 1.03% |
| Week | 1.31% | 1.76% |
| Month | 5.12% | 9.54% |
| 3 Months | 10.07% | 20.61% |
| 6 Months | 16.35% | 29.79% |
| Year | 25.42% | 41.76% |
| 3 years | 37.78% | 90.20% |
| 5 years | 49.50% | 117.61% |
| All time | — | — |
- Sortino
- -1.12
- Sharpe
- -1.49
- Sterling
- -0.20
- Liquidity index
- 7.38
- Alpha
- 0.00129
- Beta
- 0.29
AI Factors
Drivers of growth or decline are external factors, selected using AI, that can significantly affect the price of a company's shares in the future.
Fundamental analysis
Indicators for the last quarter and their dynamics for 5 quarters
Ratios
Valuation
Debts
Efficiency
Other ratios
Revenue
Financials
Growth
Assets
Debts
News
About
$196.70B
Capitalization
2.52B
Shares outstanding
Health Care
Sector
Pharmaceuticals
Industry
US58933Y1055
ISIN
1
Lot size
Mr. Robert M. Davis J.D.
CEO
Website
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.